The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities.

Autor: Ramberger E; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, DKFZ and Charité - Universitätsmedizin Berlin, Berlin, Germany., Sapozhnikova V; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, DKFZ and Charité - Universitätsmedizin Berlin, Berlin, Germany., Ng YLD; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Dolnik A; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Ziehm M; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; Berlin Institute of Health, Berlin, Germany., Popp O; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; Berlin Institute of Health, Berlin, Germany., Sträng E; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Kull M; Internal Medicine III, University Hospital Ulm, Ulm, Germany., Grünschläger F; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Krüger J; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Benary M; Berlin Institute of Health, Berlin, Germany., Müller S; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Gao X; Internal Medicine III, University Hospital Ulm, Ulm, Germany., Murgai A; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, DKFZ and Charité - Universitätsmedizin Berlin, Berlin, Germany., Haji M; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; Berlin Institute of Health, Berlin, Germany., Schmidt A; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Lutz R; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Nogai A; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Braune J; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Laue D; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Langer C; Internal Medicine III, University Hospital Ulm, Ulm, Germany., Khandanpour C; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany., Bassermann F; Department of Medicine III, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany., Döhner H; Internal Medicine III, University Hospital Ulm, Ulm, Germany., Engelhardt M; Freiburg University Hospital, Freiburg, Germany., Straka C; Medizinische Klinik, München Klinik Schwabing, Munich, Germany., Hundemer M; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Beule D; Berlin Institute of Health, Berlin, Germany., Haas S; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, DKFZ and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute of Health, Berlin, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany., Keller U; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, DKFZ and Charité - Universitätsmedizin Berlin, Berlin, Germany., Einsele H; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany., Bullinger L; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, DKFZ and Charité - Universitätsmedizin Berlin, Berlin, Germany., Knop S; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany. stefan.knop@klinikum-nuernberg.de.; Nuremberg General Hospital, Nuremberg, Germany. stefan.knop@klinikum-nuernberg.de.; Paracelsus Medical School, Nuremberg, Germany. stefan.knop@klinikum-nuernberg.de., Mertins P; Max Delbrück Center for Molecular Medicine, Berlin, Germany. philipp.mertins@mdc-berlin.de.; Berlin Institute of Health, Berlin, Germany. philipp.mertins@mdc-berlin.de., Krönke J; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. jan.kroenke@charite.de.; German Cancer Consortium (DKTK), partner site Berlin, DKFZ and Charité - Universitätsmedizin Berlin, Berlin, Germany. jan.kroenke@charite.de.

Publikováno v: Nature cancer [Nat Cancer] 2024 Aug; Vol. 5 (8), pp. 1267-1284. Date of Electronic Publication: 2024 Jun 28.

PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα

Autor: Ramberger, E., Sapozhnikova, V., Kowenz-Leutz, E., Zimmermann, K., Nicot, N., Nazarov, P.V., Perez-Hernandez, D., Reimer, U., Mertins, P., Dittmar, G., Leutz, A.

Publikováno v: iScience
iScience, Vol 24, Iss 6, Pp 102686-(2021)

Summary C/EBPα represents a paradigm intrinsically disordered transcription factor containing short linear motifs and post-translational modifications (PTM). Unraveling C/EBPα protein interaction networks is a prerequisite for understanding the mul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::793a638609a887d38729c4d846538f5c
http://europepmc.org/articles/PMC8220391

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.

Autor: Heynen GJJE; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Baumgartner F; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité (Junior) (Digital) Clinician Scientist Program, Berlin, Germany., Heider M; Internal Medicine III, School of Medicine, Technische Universität München, Munich, Germany., Patra U; Institute of Biochemistry II, Goethe University, Medical School, Frankfurt, Germany., Holz M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Braune J; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Kaiser M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Schäffer I; Internal Medicine III, School of Medicine, Technische Universität München, Munich, Germany., Bamopoulos SA; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité (Junior) (Digital) Clinician Scientist Program, Berlin, Germany., Ramberger E; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany., Murgai A; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Ng YLD; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Demel UM; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité (Junior) (Digital) Clinician Scientist Program, Berlin, Germany., Laue D; Department of Traumatology and Reconstructive Surgery, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., Liebig S; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Krüger J; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Janz M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany., Nogai A; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Schick M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Mertins P; Max-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany., Müller S; Institute of Biochemistry II, Goethe University, Medical School, Frankfurt, Germany., Bassermann F; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Internal Medicine III, School of Medicine, Technische Universität München, Munich, Germany., Krönke J; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Keller U; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany., Wirth M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Blood advances [Blood Adv] 2023 Feb 28; Vol. 7 (4), pp. 469-481.

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.

Autor: Ng YLD; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Ramberger E; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Proteomics Platform, Max Delbrück Center for Molecular Medicine, Berlin, Germany.; German Cancer Consortium (DKTK) partner site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany., Bohl SR; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Dolnik A; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Steinebach C; Department of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany., Conrad T; Experimentelle Pharmakologie & Onkologie (EPO) Berlin-Buch GmbH, Berlin, Germany., Müller S; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Popp O; Proteomics Platform, Max Delbrück Center for Molecular Medicine, Berlin, Germany., Kull M; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Haji M; Proteomics Platform, Max Delbrück Center for Molecular Medicine, Berlin, Germany., Gütschow M; Department of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany., Döhner H; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Walther W; Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Keller U; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK) partner site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.; Berlin Institute of Health (BIH), Berlin, Germany., Bullinger L; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK) partner site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Berlin Institute of Health (BIH), Berlin, Germany., Mertins P; Proteomics Platform, Max Delbrück Center for Molecular Medicine, Berlin, Germany. philipp.mertins@mdc-berlin.de.; Berlin Institute of Health (BIH), Berlin, Germany. philipp.mertins@mdc-berlin.de., Krönke J; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. jan.kroenke@charite.de.; German Cancer Consortium (DKTK) partner site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany. jan.kroenke@charite.de.

Publikováno v: Nature communications [Nat Commun] 2022 Feb 23; Vol. 13 (1), pp. 1009. Date of Electronic Publication: 2022 Feb 23.

Tissue specific labeling in proteomics

Autor: Ramberger, E., Dittmar, G.

Mass spectrometry-based proteomics is a powerful tool for identifying and quantifying proteins in biological samples. While it is routinely used for the characterization of simple cell line systems, the analysis of the cell specific proteome in multi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=mdc______med::cb66609426652bb0089f5c5ff7fe3622
http://edoc.mdc-berlin.de/16676/1/16676oa.pdf